Si vous ne visualisez pas cette newsletter / if you don't see this newsletter :
http://www.maunakeatech.com/news/may08/index.html

Cellvizio® News

by MKT Mauna Kea Technologies

MAY 2008

Editorial

Welcome to Cellvizio News! These are exciting times for **Mauna Kea Technologies**. When we started the company in 2000, we envisioned creating a groundbreaking technology to help physicians see inside the body in a way never before possible. Today, the vision is a reality with the **Cellvizio® endomicroscopy system.** Pioneering physicians and researchers can now visualize tissue in situ at the cellular level.

With growing interest and broadening applications, we are excited to see a portfolio of studies at the upcoming DDW. Clinical data at oral and poster sessions will show how Cellvizio can help physicians more effectively diagnose a broad range of GI diseases including Barrett's esophagus, ulcerative colitis and colorectal cancer, as well as bile duct and pancreatic cancer surveillance through ERCP.

I invite you to join leading physicians and researchers to advance new indications for this remarkable technology.

Sacha Loiseau
PhD, President, CEO and Founder

Upcoming Events

May 17-22, 2008 **Digestive Disease Week (DDW)** San Diego Convention Center, California.

Video Spotlight: Crohn's Disease



This high-resolution Cellvizio® GI mosaic image shows in vivo colon tissue at the cellular level exhibiting chronic inflammation, visible lymphatic vessels, and general scarring of surrounding tissue. The differential diagnosis is an indication of Crohn's disease. This **link** shows the real time video of this unique image obtained with the **Cellvizio GI** system.

Image courtesy of Dr. Evelien Dekker, Academic Medical Center, Amsterdam

Digestive Disease Week®

At the upcoming DDW, a number of presentations will highlight Cellvizio GI technology.

Dr. Anna Buchner of the Mayo Clinic, in Jacksonville, Florida, will highlight Cellvizio GI technology in advancing diagnosis of colorectal neoplasia in vivo. Her important work will be presented in the Late Breaking Abstract Oral Session on Tuesday,
5/20, 2:15 - 3:45pm, Room 29:

"High Resolution Confocal Endomicroscopy Probe System for In Vivo Diagnosis of Colorectal Neoplasia"

4 posters presentations are also of note, available for review on the days shown below from 8am-5pm, in the Sails Pavilion. Authors are available poster-side from noon to 2pm.

Sunday 5/18 - S1161:

"Detection of Cholangiocarcinoma in-Vivo Using Miniprobe-Based Confocal Microscopy," A Meining, Technical University of Munich."

Sunday 5/18 - S1169:

"Miniprobe Based Confocal Fluorescence Microscopy Is Feasible for Recognition of Histological Features In-Vivo for the Prediction of Final istopathology in Patients with Longstanding Ulcerative Colitis," FJ van den Broek, Academic Medical Center, Amsterdam

Visit us at booth #4013 to experience endomicroscopy with **Cellvizio GI.**

May 16-21, 2008 **American Thoracic Society (ATS)** Metro Toronto Convention Centre, Ontario.

At booth #407, learn about the emerging world of **Alveoscopy** ® with **Cellvizio® LUNG.**

Research Advances

Endoscopic Imaging of Angiogenesis In Vivo

Department of Medicine II, Technical University of Munich, and Mayo Clinic College of Medicine, Jacksonville, Florida

Drs. Alexander Meining and Michael Wallace have studied subcellular histologic markers for mucosal neoplasia. Their article reviews this type of research, which can be enhanced with Cellvizio® confocal microscopy. They note that newer Cellvizio research software allows studies currently underway into the quantification of micro-vessel density. This may enable objective evaluation of micro-vessel density with neoplastic development and anti-angiogenetic therapy.

Gastroenterology 2008 (April); 134:915-918

Sunday 5/18 - S1392:

"Accuracy of Miniprobe Confocal Laser Microscopy for Detection of Barrett Neoplasia,"
Histopathology Pohl, Veterans Administration Medical Center, White River Junction, Vermont

Monday 5/19 - M1316:

"Confocal Laser Microscopy Guided Endoscopic Mucosal Resection in Barrett's Esophagus with High Grade Dysplasia,"
RJ Badreddine, Mayo Clinic; Rochester, Minnesota

Clinical Advances

Colon Cancer Detection Earlier, Faster,

Stanford University School of Medicine, California

The combination of targeted peptide probes with Cellvizio® GI imaging provides a powerful tool with the potential to improve the early detection of cancer. This new clinical study reports colon cells probed with peptides in vivo and imaged with Cellvizio GI can detect early stage cancerous polyps in real time. Results were well correlated with biopsies in the initial trial of 15 patients. Christopher Contag, PhD, anticipates that the technique may be expanded to assess signs of neoplasm earlier, evaluate chemotherapeutic effects and refine cancer treatments.

Full report available at www.nature.com/naturemedicine

Nature Medicine 2008 Apr;14(4):454-8.

Product Development

Cellvizio® GI ERCP Mini-Probe Debuts

At DDW, a specially designed mini-probe debuts that enables the Cellvizio GI system to be used with endoscopic retrograde cholangiopancreatography (ERCP). This new mini-probe allows imaging of pancreatic and biliary structures, previously difficult to visualize. This new mini-probe fits standard duodeno-scopes, cholangioscopes and ERCP catheters, so workflow does not change. The new mini-probe should enable clearer differentiation of structures and improve diagnosis of neoplasia of the pancreatic and biliary ducts.

Physician Q and A

Dr. Alexander Meining, Technical University of Munich

Q. What did you feel when you were first introduced to Cellvizio® GI?
A. *I was amazed, because you see moving, living cells in vivo during an ongoing endoscopy. I had the impression that I was detecting an absolutely new world of endoscopic imaging. It's very easy to use, and you get good images rather fast.*

Q. Can Cellvizio be used with other enhanced endoscopic techniques, such as narrow band imaging?
A. *Cellvizio has the advantage that we may use it with any kind of endoscope, and other enhanced imaging technologies, such as narrow band imaging and autofluorescence.*

Corporate News

Mauna Kea Technologies, based in Paris, is increasing its commercialization efforts in the U.S. In early 2008, Chris Tihansky was named President of its U.S. subsidiary, Cellvizio Inc., based in the Philadelphia area. He can be reached at +1 (888) 590-1798 or by email: **tihansky@maunakeatech.com**

Chris has 20 years of experience in emerging medical technology and healthcare financial services. He most recently served as President and CEO of Surgical Services Inc., a division of Teleflex Inc. Chris received a Bachelor of Science Degree in Mechanical Engineering from Lehigh University; a Master of Science Degree in Biomedical Engineering from Drexel University; and an MBA from the University of San Diego.

Chris Tihansky MS, MBA, President, Cellvizio Inc.

Mauna Kea Technologies

9, rue d'Enghien
75010 Paris, France

Tel France :
+33 (0)1 48 24 03 45

Mauna Kea Technologies

www.maunakeatech.com

Cellvizio, Inc. (U.S. Subsidiary)

41 University Drive, Suite 400
Newtown, PA 18940

Phone USA:
+1 (888) 590 1798